Physician profile
Javier Sobrado
NPI 1689636391
$8,565.62
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,426 · 2020: $1,868 · 2021: $1,893 · 2022: $1,378.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gi Supply, INC. | $2,100.34 | 2019-2020 | |
| Abbvie INC. | $1,792.33 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,116.21 | 2019-2022 | |
| Qol Medical, LLC | $626.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $500.82 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $327.02 | 2020-2021 | |
| Gilead Sciences, INC. | $248.24 | 2019-2022 | |
| Janssen Biotech, INC. | $225.03 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $224.11 | 2019-2022 | |
| Braintree Laboratories, INC. | $176.09 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $133.38 | 2019-2021 | |
| Perspectum Diagnostics LTD | $119.33 | 2022 | |
| Boston Scientific Corporation | $112.54 | 2019 | |
| Redhill Biopharma INC. | $111.64 | 2020-2022 | |
| Axonics, INC. | $108.21 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $103.76 | 2019-2022 | |
| Allergan, INC. | $76.53 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $72.04 | 2020-2022 | |
| Ardelyx, INC. | $66.68 | 2022 | |
| Genzyme Corporation | $43.68 | 2022 | |
| Ucb, INC. | $43.25 | 2019 | |
| Janssen Scientific Affairs, LLC | $39.18 | 2019 | |
| Celgene Corporation | $38.27 | 2021-2022 | |
| Alfasigma USA, INC. | $36.97 | 2021 | |
| Evoke Pharma, INC. | $35.40 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $24.51 | 2022 | |
| Ethicon US, LLC | $24.06 | 2019 | |
| Endo Pharmaceuticals INC. | $22.86 | 2019 | |
| Pfizer INC. | $17.06 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Research and ownership
$16,439.36 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Sobrado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.